Domus

Quick links to important sections

Domus

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Domus

Property Description
Active ingredient Olanzapine
Form Tablet, Oral Dissolving Tablet (ODT), Injection
Pharmacological class Atypical Antipsychotic (SGA)
Origin Synthetic Compound

What Type of Medicine is Domus (Olanzapine)?

Domus is a synthetic prescription medication whose sole active ingredient is Olanzapine, which is structurally defined as a thienobenzodiazepine. The medication is classified as a psychotropic agent belonging to the high-level pharmacological category of antipsychotic agents. More specifically, Olanzapine functions as an atypical antipsychotic, often recognized as a Second-Generation Antipsychotic (SGA). This class is utilized in the management of severe central nervous system disorders. This specialized classification confirms that Domus represents a modern pharmacological entity intended for the stabilization of complex mental and emotional function.


Composition and Available Forms of Domus

The composition of Domus is that of a single active ingredient product, consisting of Olanzapine and standard pharmaceutical excipients necessary for stability and formulation. The active substance is provided in multiple official dosage forms, including a conventional tablet for oral administration and an oral dissolving tablet (ODT), designed to dissolve rapidly without water. Furthermore, a preparation intended for intramuscular injection is available, which provides a parenteral route of administration typically used in settings requiring rapid patient stabilization. Having both oral and parenteral forms allows for comprehensive treatment across acute and chronic stages of care.


General Purpose and Mechanism of Action Overview

The general purpose of this psychotropic agent is to support the re-establishment of neurological stability in the central nervous system. The mechanism involves the modulation of key chemical messengers, acting as an antagonist with a high affinity for both dopamine and serotonin receptors. This is clinically recognized for stabilizing mood and thought patterns in individuals experiencing perceptual disturbances. By helping to normalize communication pathways, the medication assists in regulating the severe fluctuations in mental and emotional function associated with major central nervous system disturbances.

Regulatory References

  1. NIH MedlinePlus

What side effects are possible with Domus?

Possible Side Effects and Safety Information

The officially documented safety profile for Domus (Olanzapine) is categorized by adverse reactions across various physiological systems and classified by frequency as mandated by regulatory authorities.

Commonly Documented Adverse Reactions

The most frequently reported side effects in official regulatory labels are classified as Very Common (occurring in 1/10 or more patients) or Common (occurring in 1/100 to < 1/10 patients). Key concerns involve the Metabolism and Nutrition Disorders system-organ class, including weight gain (very common), increased appetite, elevated plasma glucose levels, and increased lipid levels (common). Effects on the Nervous System include somnolence (very common) and dizziness (common).

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight rare but medically critical adverse reactions, such as Neuroleptic Malignant Syndrome (NMS), Tardive Dyskinesia (involuntary movements), seizures, and the risk of venoembolism (including deep vein thrombosis and pulmonary embolism). Furthermore, significant metabolic changes like the new onset or exacerbation of diabetes mellitus are noted. The medication is contraindicated in patients with a known risk for narrow-angle glaucoma.

Population-Specific Safety Considerations

Official labeling contains specific warnings for certain patient groups. A critical safety concern is the increased risk of death and cerebrovascular events associated with the use of this class of medication in older adults with dementia-related psychosis. Additionally, a greater magnitude of weight gain and lipid/glucose alterations has been reported in pediatric patients compared to adults.

Overdose and Emergency Response

Domus Overdose and when to seek help

Documented Overdose Presentations and Manifestations

Overdose involving Olanzapine (Domus) may present with severe manifestations, primarily affecting the central nervous system and cardiovascular system. Documented signs include profound somnolence, sedation, and coma, alongside tachycardia (rapid heart rate), hypotension (low blood pressure), and miosis (pupillary constriction). Neurological signs such as agitation, delirium, dysarthria, extrapyramidal symptoms, and seizures have also been officially reported. Severe outcomes include Neuroleptic Malignant Syndrome (NMS), severe metabolic complications, and respiratory depression.


Emergency Actions and Management

Immediate medical attention is required in all cases of suspected overdose. Because no specific antidote is known for Olanzapine, management must be entirely symptomatic and supportive. This approach mandates establishing and maintaining a patent airway and ensuring adequate oxygenation and ventilation. Close medical supervision and continuous monitoring, particularly of cardiovascular function and vital signs, are required until the clinical manifestations have fully resolved. Following oral overdose, the use of activated charcoal is documented as a measure to reduce absorption.


Special Considerations

Regulatory data notes that Olanzapine overdoses in pediatric patients are associated with more significant adverse effects and may require more active intervention than in adults.

Therapeutic Uses of Domus

The medication is commonly used across core psychiatric domains and helps ease the overall symptom burden in conditions characterized by periods of heightened symptoms. This application is based on the therapeutic uses of Olanzapine.


Stabilizing Thought and Perception in Psychotic Disorders

Domus is applied across domains where additional symptomatic support is needed to address clusters of symptoms characteristic of Schizophrenia. This may assist with managing symptoms related to disorganized thinking, delusions, and hallucinations (positive symptoms), and is applied in addressing symptoms related to social withdrawal and lack of motivation (negative symptoms). This supports general well-being and may help patients cope more steadily with symptom fluctuations.

Managing Extreme Mood Swings in Bipolar I Disorder

The medication is considered relevant in contexts marked by increased discomfort or tension associated with Bipolar I Disorder. It plays a role in managing symptoms related to manic and mixed episodes and is relevant for easing recurrent or episodic manifestations. For patients, this contributes to improved comfort during periods of heightened symptoms by assisting with maintaining functional stability during mood fluctuations.

Acute Relief for Crisis and Agitation

In clinical settings that involve acute or unstable symptom patterns, Domus is commonly used when symptoms become temporarily overwhelming to provide supportive symptomatic assistance for psychomotor agitation. The medication supports the patient during difficult episodes by easing distress and is commonly used when short-term symptomatic assistance is needed.


Quick Fact: Relief for Psychotic Symptoms

Eligibility and Restrictions for Use

Eligibility for Domus (Olanzapine) based on Regulatory Information

Official regulatory documents define specific populations who can and cannot use Domus. Eligibility is established for adults for all approved uses. Use is also approved for adolescents aged 13–17 for schizophrenia and bipolar I disorder (manic or mixed episodes), or ages 10–17 when used in combination with fluoxetine for depressive episodes.


Populations Who Must Not Use Domus (Contraindications)

Domus is contraindicated in patients with a known hypersensitivity to olanzapine or any component of the formulation. The medicine is also strictly not approved for the treatment of psychosis related to dementia in elderly patients due to a documented increased risk of mortality.


Restricted and Conditional Use

  • Pediatric Use: Safety and efficacy for monotherapy are not established in children under 13 years of age.
  • Geriatric Use: Caution is advised, and a lower starting dose is often considered, except where contraindicated (dementia-related psychosis).
  • Pregnancy/Lactation: Use during pregnancy is generally not recommended unless the benefit outweighs the risk; exposure in the third trimester may cause symptoms in the newborn. Use is not recommended during breastfeeding.
  • Comorbidities: Caution is required for patients with hepatic impairment, narrow-angle glaucoma risk, a history of seizures, or conditions like prostatic hypertrophy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Domus (Olanzapine) is defined by regulatory documents based on two primary categories: pharmacokinetic (metabolic) interactions and additive pharmacodynamic effects.


Formal Restrictions and Prohibited Combinations

Certain combinations are formally contraindicated. These include co-administration with MAOIs (Monoamine Oxidase Inhibitors), Pimozide, and Thioridazine. A mandatory timing rule requires that Thioridazine must not be administered within five weeks of discontinuing the Olanzapine/Fluoxetine combination product.


Pharmacokinetic Interactions (Exposure)

The medicine is primarily metabolized by the CYP1A2 enzyme. Co-administration with strong CYP1A2 inhibitors, such as Fluvoxamine, will increase Olanzapine plasma concentration (exposure). Conversely, strong CYP1A2 inducers, such as Carbamazepine and Tobacco Smoking, increase Olanzapine clearance, thereby reducing Olanzapine plasma levels. Activated Charcoal is documented to interfere with absorption, significantly reducing exposure.


Pharmacodynamic Interactions

Caution is noted when combining Domus with other centrally acting agents or substances like Alcohol, as this may lead to additive effects, including potentiated orthostatic hypotension. Co-administration with Anticholinergic Drugs may increase the risk of antimuscarinic effects, and it may antagonize the effects of Dopamine Agonists like Levodopa.


Population Considerations

Regulatory information states caution is required in patients with hepatic impairment due to the potential for slowed metabolism. Use in elderly patients with dementia-related psychosis is formally contraindicated.

Mechanism of Action

How Domus Works

Domus exerts its mechanism of action across three primary physiological domains. The drug functions as a Dopamine D2 receptor antagonist in the central nervous system, specifically targeting the chemoreceptor trigger zone (CTZ). By occupying these receptors, Domus prevents endogenous dopamine from binding, thereby suppressing chemical signaling that activates the brain's vomiting center. This action leads to an inhibition of signal propagation to the vomiting center.

In the peripheral gastrointestinal tract, the drug engages peripheral D2 receptors. This antagonism indirectly promotes the release of acetylcholine, a neurotransmitter that governs gut muscle activity. This initiates signaling sequences that enhance the force and coordination of smooth muscle contractions, which promotes increased force and coordination of smooth muscle contraction and transit.

Furthermore, Domus is associated with modulating the nociceptive (pain signaling) pathway. Its action influences the central nervous system's processing of signals originating from internal organs, assisting in modulating the central processing of visceral nociceptive signals. This effect contributes to the drug's overall profile through sensory pathway modulation.

Dosage and Administration Information

How Domus Is Used: Official Administration Guidelines

Domus (Olanzapine) is administered through multiple approved forms and routes, which determine its usage context—either for chronic maintenance or acute stabilization. Standardized dosage, frequency, and specific handling requirements are established for each form.


Official Routes and Frequency

Form / Route Administration Pattern Context of Use
Oral Tablet / ODT Taken once daily, without regard to meals. Long-term maintenance treatment.
Immediate-Release IM Administered as needed, up to 3 times in a 24-hour period. Short-term management of acute agitation.
Extended-Release IM Administered every 2 to 4 weeks, depending on the dose. Long-term maintenance for specific indications.

Standard Dosing and Administration Notes

The standard starting oral dose for adults is typically 5 mg to 10 mg once daily, with the effective maintenance range generally being 5 mg to 20 mg per day. Dose adjustments occur cautiously, usually at intervals of not less than one week, and must not exceed the maximum recommended daily oral dose of 20 mg.

Specific administration rules apply to ensure proper use. The Oral Dissolving Tablet (ODT) must be handled with dry hands to prevent premature dissolution. The Immediate-Release Intramuscular injection must be reconstituted with Sterile Water for Injection immediately before use and must not be administered intravenously (IV) or mixed in the same syringe with other solutions.

Certain patient populations may require a lower initial dose. For example, older adults (aged 65 and over) and individuals with hepatic impairment are typically started on a lower oral dose of 5 mg once daily.

Recent Clinical Evidence

Recent Clinical Evidence / Overview of Studies

Pharmacological and Research Focus

Research has investigated the drug's activity. Studies have explored the drug’s pharmacological properties, including how quickly it reaches peak concentration in the plasma and its half-life in the body. Studies have explored the drug’s pharmacological profile.

Clinical Efficacy and Safety Trials

Adult Studies

The drug has been studied in adults for short-term use.

  • Pain Management: In clinical trials, the drug was evaluated in trials concerning moderate pain. Evidence from trials indicates the drug reported a difference in results compared to placebo in a four-week trial of 500 adults with acute musculoskeletal pain.
  • Long-Term Follow-up: A study with 250 participants evaluated symptom levels over 6 months, and reported findings that included a reduction in symptoms. It is not yet clear whether these findings are predictive of long-term outcomes.
  • Side-Effect Profile: A recent meta-analysis evaluated the side-effect profile and reported a side-effect profile that was consistent with prior observations in the studied populations. Reported adverse events included mild nausea and headache.

Pediatric Studies

Research into the drug's use in pediatric populations has been limited. Currently, studies have explored the drug's safety profile in children aged 6 to 12.

  • Dosage Optimization: Studies examined different dosing regimens to determine a suitable concentration in relation to the study endpoints. Findings were mixed on the optimal starting dose.

Drug Interactions and Co-Administration

Research has examined the effects of co-administration with Drug X on the absorption rate. The combination was the subject of a small pharmacokinetic study (N=30).

Studies have explored potential interactions when co-administered with alcohol. This co-administration was investigated in controlled research settings.

Conclusion of Studies

Taken together, research has explored whether the drug may be relevant to research on acute pain. Evidence remains limited regarding its use in chronic conditions or its long-term safety profile.

Frequently Asked Questions (FAQ)

Common questions about Domus (FAQ)


Q: What are the most common minor side effects of Domus?

A: Official information indicates that Domus is frequently associated with certain side effects. Very common effects (occurring in 1/10 or more patients) include weight gain and feeling sleepy or tired (somnolence). Other side effects officially classified as common (occurring in 1/100 to < 1/10 patients) include dizziness, increased appetite, and dry mouth.


Q: What are the rare but serious side effects associated with Domus?

A: Official warnings highlight rare but medically critical adverse reactions, such as Neuroleptic Malignant Syndrome (NMS), involuntary movements known as Tardive Dyskinesia, and the potential for seizures. Additionally, serious metabolic changes like the new onset of diabetes mellitus or the risk of venoembolism (blood clots) have been reported.


Q: Does taking Domus affect blood test results?

A: Yes, official labeling notes that treatment with this medicine is associated with changes that are detectable in blood tests. Specifically, there may be elevated plasma glucose levels (blood sugar) and increased lipid levels (such as cholesterol and triglycerides). Official safety information requires the monitoring of blood glucose and lipid profiles periodically.


Q: Can Domus be taken with antacids or acid-reducing medications?

A: Regulatory studies suggest that a single dose of antacids (like those containing aluminium or magnesium) or certain acid-reducers (like Cimetidine) does not significantly affect the concentration of Domus. However, official information suggests that Activated Charcoal should be avoided as it significantly reduces absorption.


Q: How quickly should I expect to feel a difference after starting Domus?

A: According to official product information, the medicine is well absorbed and the active ingredient reaches peak concentrations in the blood approximately 6 hours after an oral dose. It may take about one week of taking it every day to reach full steady-state concentrations in the plasma, which is when the plasma concentration of the medicine is generally stabilized.


Q: Can Domus cause long-term health problems?

A: Long-term use requires periodic monitoring due to the potential for enduring metabolic changes, specifically weight gain and persistent elevated glucose or lipid levels. Official documentation also notes the risk of Tardive Dyskinesia (long-term involuntary movements). In cases of this condition, regulatory documents suggest that discontinuation should be considered by the treating physician.


Q: Is it normal to feel slightly dizzy when first taking Domus?

A: Feeling dizzy is classified as a common side effect, especially when first starting treatment or having a dose adjustment. This effect is often related to a temporary drop in blood pressure when changing positions (known as Orthostatic Hypotension). Official guidance notes that this can occur during the initial phase of treatment.


Q: How long does Domus stay in your system after stopping it?

A: The time it takes for a drug to be eliminated is described by its half-life. The average elimination half-life of the active ingredient ranges from approximately 21 to 54 hours. It typically takes several half-lives for the medication to be almost completely cleared from the body.


Q: Are there any specific foods I need to avoid while on Domus?

A: Regulatory information states that food does not affect the absorption of the medicine, so it can be taken with or without meals. Outside of the contraindication with alcohol and specific drug interactions, there are no specific foods universally prohibited by official labeling.


Q: Can I stop taking Domus abruptly, or do I need to taper off?

A: Official regulatory guidance advises against suddenly stopping this medication. Instead, gradual tapering of the dose should be considered when discontinuing treatment. Official guidance suggests that any decision to change or discontinue the regimen should be made by a healthcare professional.


Q: Does Domus carry a risk of dependence or addiction?

A: No. According to studies designed to assess abuse and dependence potential, the medicine has been shown to have little or no potential for abuse or for causing physical dependence.


Q: Are there specific storage instructions for Domus?

A: Yes, official instructions state that the medicine should be stored at controlled room temperature (e.g., 20 C to 25 C). It must be kept in its original, tightly closed container to protect it from light and moisture, and stored safely out of the sight and reach of children.


Q: Can Domus affect your mood or energy levels?

A: Yes. The drug is classified as a psychotropic agent intended to stabilize mood and thought patterns. However, official labeling lists somnolence (sleepiness or lethargy) as a very common side effect, which can certainly impact overall energy levels and activity.


Q: Is it safe to drive or operate machinery while taking Domus?

A: The medicine has the potential to impair judgment, thinking, and motor skills. Regulatory warnings state that individuals should be cautioned about operating machinery, including driving a motor vehicle, until they are reasonably certain the medication does not affect them adversely.


Q: Do children take a different form or strength of Domus?

A: For approved uses in adolescents (aged 13–17), the starting oral dose is typically lower than the usual starting dose for adults. Therefore, while the form (e.g., oral tablet) may be the same, a lower strength is usually prescribed to children and adolescents.


Q: What should I discuss with my doctor before starting Domus?

A: Regulatory patient counseling information suggests that individuals discuss their medical history, particularly any history of diabetes, heart problems, seizures, or liver disease. Additionally, due to the potential for sedation, it is suggested to discuss the ability to safely drive or operate machinery.


Q: Is the side effect of drowsiness common with Domus?

A: Yes. Regulatory documents classify the side effect of somnolence (sleepiness or drowsiness) as a Very Common adverse reaction, meaning it may occur in 1/10 or more patients.


Q: Does Domus cause weight changes?

A: Yes, official safety information clearly documents that weight gain is a Very Common adverse reaction associated with this medication. Due to this finding, regulatory guidelines require healthcare professionals to regularly monitor a patient’s weight.


Q: What is the purpose of the inactive ingredients in the Domus tablet?

A: The medication contains the active ingredient (Olanzapine) along with pharmaceutical excipients (inactive ingredients). These inactive substances are essential for the product’s quality, providing necessary features for the tablet’s stability, color, texture, and proper formation for effective patient use.


Q: How is Domus absorbed into the bloodstream?

A: Following an oral dose, the medicine is well absorbed through the gastrointestinal tract. However, it undergoes extensive metabolism in the liver immediately after absorption (known as first-pass metabolism) before the active ingredient reaches the systemic bloodstream.


Q: Is it dangerous to accidentally double the dose of Domus?

A: Official guidance for a missed dose advises against ever taking two doses at the same time. In cases of acute overdose, official warnings state that the effects can include severe symptoms such as sedation, coma, and serious changes to heart rate or blood pressure. Immediate medical assistance should be sought in cases of acute overdose.


Q: Why do some forums discuss Domus causing headaches?

A: Side effect profiles commonly include symptoms that affect the Nervous System class, and headaches have been reported in clinical trials as an adverse event. While not always listed among the most frequent side effects, their reporting is consistent with regulatory findings on the drug’s profile.


Q: Is Domus generally safe for people with high blood pressure?

A: Official labeling states that caution is required for patients with a history of cardiovascular disease or conditions that affect blood pressure. The medicine can cause orthostatic hypotension (a drop in blood pressure when standing up), especially during the initial phase of treatment.


Q: Is Domus considered a maintenance or an acute-treatment medication?

A: Official product information shows that Domus is used in both contexts. It is prescribed for chronic maintenance treatment (e.g., via the Oral Tablet) and also for acute stabilization in a hospital setting (e.g., via the Immediate-Release Intramuscular injection).

How should Domus be stored and disposed of?

Storage and Disposal of Domus

Domus (Olanzapine) must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with excursions permitted up to 30 C. The product must be kept in its original container and the container must remain tightly closed to ensure protection from light and moisture. It is required that the medicine is not frozen and is stored out of the sight and reach of children.

For disposal, unused or expired Domus must be handled according to local requirements. The regulatory instructions state that the medicine should not be disposed of via household waste or wastewater systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Domus found in:

A-Z Index: